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ABSTRACT
Idiopathic sudden sensorineural hearing loss (ISSNHL) is considered to be an otological emergency. The intratympanic 
(IT) steroid injection technique is introduced to decrease the side effects of systemic steroids and assumed to deliver 
a higher concentration of corticosteroids into the affected cochlea. The objective of the current study was to evaluate 
the hearing outcomes of high dose IT methylprednisolone among ISSNHL patients after failure of systemic corticosteroid 
therapy (SCT). Hearing outcomes of SCT were evaluated over a 15 months period. Upon failure of SCT, the treatment was 
continued with higher dose IT steroid (methylprednisolone 62.5 mg/mL). Pre-treatment and post-treatment audiometric 
evaluations were analysed using pure tone audiogram (PTA). There were 36 patients diagnosed with ISSNHL included 
in the study. After two weeks of SCT, eighteen (56.3%) patients had hearing improvement of more than 10 dB. Another 
fourteen (43.7%) patients had no hearing improvement (less than 10 dB). Following that, twelve patients were recruited 
for weekly IT methylprednisolone for three weeks. During the one month follow up after completion of IT therapy, six 
patients (50%) showed more than 10 dB improvement in the PTA with a mean of 19.37 dB (p<0.05). Out of the six, two 
patients had more than 20 dB hearing improvement. Almost all patients in this study had an improvement in their symptoms 
of tinnitus and vertigo. High dose IT methylprednisolone after failure of SCT resulted in significant improvement in the 
patients’ hearing outcome during one month follow up. The IT therapy not only improved the patients’ hearing but in 
addition reduced the symptoms of tinnitus and vertigo. 
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ABSTRAK
Kehilangan pendengaran  sensorineuron mengejut idiopati (ISSNHL) dianggap sebagai kecemasan otologi. Teknik suntikan 
steroid intratimpanum (IT) diperkenalkan untuk mengurangkan kesan sampingan steroid sistemik dan diandaikan memberi 
tumpuan yang lebih tinggi daripada kortikosteroid ke koklea yang terjejas. Objektif kajian adalah untuk menilai hasil 
pendengaran dos yang tinggi metilprednisolon IT dalam kalangan pesakit ISSNHL selepas kegagalan terapi sistemik 
kortikosteroid (SCT). Laporan hasil SCT telah dinilai dalam tempoh 15 bulan. Atas kegagalan SCT, rawatan diteruskan 
dengan dos IT steroid yang tinggi (metilprednisolon 62.5 mg/mL). Penilaian pra dan pasca rawatan audiometrik 
dianalisis menggunakan audiogram bernada tulen (PTA). Terdapat 36 pesakit yang didiagnosis dengan ISSNHL terlibat 
dalam kajian ini. Selepas dua minggu SCT, lapan belas (56.3%) pesakit mempunyai peningkatan pendengaran melebihi 
10 dB. Empat belas (43.7%) pesakit lain tidak mempunyai sebarang kemajuan pendengaran (kurang daripada 10 dB). 
Berikutan itu, dua belas pesakit telah diambil bekerja untuk mingguan IT metilprednisolon selama tiga minggu. Pada 
bulan pertama susulan selepas selesai terapi IT, enam pesakit (50%) menunjukkan lebih daripada 10 dB peningkatan 
dalam PTA dengan min 19.37 dB (p<0.05). Daripada enam, dua pesakit mempunyai lebih daripada 20 dB penambahbaikan 
pendengaran. Hampir semua pesakit dalam kajian ini menunjukkan penambahbaikan dalam gejala tinitus dan vertigo 
mereka. Dos tinggi IT metilprednisolon selepas kegagalan SCT telah mengakibatkan peningkatan yang ketara dalam 
keputusan pendengaran pesakit sepanjang sebulan susulan. Terapi IT bukan sahaja memperbaiki pendengaran pesakit 
tetapi mengurangkan gejala tinitus dan vertigo. 
Kata kunci: Intratimpanum; metilprednisolon; kehilangan pendengaran mengejut
INTRODUCTION
In Otolaryngology and Audiology practices, Idiopathic 
Sudden Sensorineural Hearing Loss (ISSNHL) is considered 
to be an otological emergency. ISSNHL is defined as a 
decline in hearing over a period of 72 h or less and affecting 
3 or more frequencies by 30 dB or greater (American 
Hearing Research Foundation). Approximately 5-20 
persons in 100,000 populations of patients who suffer from 
ISSNHL consult an otolaryngologist yearly (Abdullah et al. 
2006; Chau et al. 2010; Kuhn et al. 2011).
 Considering that there is no standard protocol or 
universally accepted way to treat patients with ISSNHL, 
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various therapies and agents such as steroids (systemic 
and local intratympanic), plasma expander, antiviral 
agents, anticoagulants, vasodilators, diuretics, vitamins, 
hyperbaric oxygen therapy and topical insulin-like growth 
factor therapy have been proposed as therapeutic agents to 
treat sudden sensorineural hearing loss (Ferri et al. 2012; 
Rausch et al. 2011). 
 Systemic glucocorticoid is the most commonly 
used treatment for ISSNHL, since most cases of ISSNHL 
are due to an infectious, inflammatory or autoimmune 
process. In such cases, ISSNHL is usually treated with 
prednisolone or dexamethasone where the recommended 
dosage varies from 1 to 10 milligrams per kilogram of 
body weight. Improvements in hearing after systemic 
corticosteroid therapies, occurs in 50% of patients. 
However, approximately 20% of patients showed no 
improvement at all (Battaglia et al. 2008; Kong et al. 2014; 
Wang et al. 2016).
 Use of intratympanic (IT) steroid was evident since year 
1991. Over the past decades, IT corticosteroid treatment is 
beginning to be more accepted in the treatment of ISSNHL 
due to the low probability of systemic adverse events and 
also due to the potential delivery of high concentrations 
of corticosteroid into the inner ear (Arastou et al. 2013). 
However, studies done on IT corticosteroid employed a 
wide variation in terms of the dosage. To the best of our 
knowledge, no study has been done with IT steroid dosage 
of more than 60 mg/mL concentration. Thus, in the current 
study, the highest concentration of steroid available is 
employed to evaluate the possible hearing improvement 
outcomes as well as its possible side effects.
 In ISSNHL, tinnitus and vertigo is the most common 
associated symptoms with 72-84% of patients suffering 
from tinnitus (Bennet et al. 2005; Mazita et al. 2008; Wan et 
al. 2013) and 40% patients complain of dizziness, vertigo, 
disequilibrium, imbalance or Meniere’s like vertigo. Two 
studies suggested that IT steroid is also a good modality 
option in treating ISSNHL patients with Meniere like vertigo 
and tinnitus (Deenadayal et al. 2016; Noell et al. 2003; 
Ruszymah et al. 2005). 
PATIENTS AND METHODS
This clinical descriptive study was approved by the 
KPJ University College (KPJUC) Ethical Committee 
(KPJUC/M.ORL/EC/2015/004). The study was carried 
out in the Otorhinolaryngology Clinic, KPJ Ampang Puteri 
Specialist Hospital from 1st of March 2015 to 30th June 
2016. Universal sampling technique was used in this 
study and consents were taken from the patients prior to 
the onset of study. The patients’ age ranged between 18 
and 60 years old, with ISSNHL of more than 30 dB at three 
consecutive frequencies within 3 days with normal hearing 
in the contralateral ear. IT steroid injections were given in 
patients with recovery of less than 10 dB after a two week’s 
treatment of systemic steroid.
 After a complete history taking, clinical examinations, 
pure tone audiogram (PTA) and several laboratory 
investigations (full blood count, coagulation profile, serum 
glucose, antinuclear antigen and serology for syphilis) were 
done.  Magnetic resonance imaging (MRI) examinations 
of brain and cerebellopontine angle was performed on all 
patients to rule out intracranial retrocochlear pathology.
SYSTEMIC CORTICOSTEROIDS THERAPY
All the ISSNHL patients were given a two-week course of 
systemic steroid therapy of intravenous dexamethasone 
for 1 week and continued with oral prednisolone of 10 
mg/body weight in tapering dose for another 8 days. 
Esomeprazole, 40 mg BD for two weeks, was given to the 
patients with risks of developing gastritis.
 PTA is repeated after completion of two-week systemic 
steroid and patients with less than 10 dB improvement in 
PTA, averaged at four tested frequencies (500, 1000, 2000 
and 4000 Hz) were included in the IT methylprednisolone 
study.
INTRATYMPANIC METHYLPREDNISOLONE INJECTION
Examinations of ears done under microscope and the 
external ear canal were cleansed using normal saline and 
suction under microscope.
 The patient was placed in supine position, with 
the head tilted 45 degrees to the healthy ear side. Local 
anaesthesia was administrated using 5% EMLA cream (1 
g contains 25 mg of Lidocaine and 25 mg of prilocaine) 
pasted on the tympanic membrane and outer ear canal. A 
3 cc syringe filled with methylprednisolone (62.5 mg/mL) 
attaches to a 25G spinal needle and around 0.3-0.5 mL of 
methylprednisolone was injected into middle ear cavity at 
the anterior inferior quadrant of the tympanic membrane. 
The patient then lied laterally on the healthy site for 30 min 
after the procedure and was instructed to avoid yawning, 
coughing and speaking for 30 min. The procedure was 
repeated weekly for 3 weeks.
 An improvement of 20 dB or the hearing thresholds 
below 20 dB (normal hearing) in the PTA average at 0.5, 
1.0, 2 and 4 kHz was considered as an improvement in 
hearing.
STATISTICAL ANALYSIS
IBM SPSS statistics version 23 and Microsoft Excel was used 
for data analysis. The comparison of mean PTA average 
before and after SCT and IT methylprednisolone therapy 
were assessed with Wilcoxon Signed Rank Test due to 
a smaller sample size. A p value ≤ 0.05 was considered 
significant. All the result are being expressed as mean 
+/- SEM.
RESULTS
Among the total of 4436 patients that visited the 
otorhinolaryngology outpatient clinic during our study 
period, 350 were with hearing problems and 36 (0.81%) 
were diagnosed with ISSNHL. There were 23 (63.9%) 
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female and 13 (36.1%) male patients. The most common 
associated symptom in the patients was tinnitus which was 
seen in 28 out of 36 patients (77.8%), followed by vertigo 
in eight out of 36 (22.2%) patients. About 11.1% of patients 
had history of associated upper respiratory tract infection 
symptoms. There was only one patient (2.7%) who had 
associated history of otalgia. 
 A total of 32 patients completed the two weeks course 
of SCT. Eighteen patients (56.3%) had improvement 
of more than 10 dB in PTA average measurement post-
treatment. Fourteen (43.7%) patients had no improvement 
or an average improvement in PTA of less than 10 dB. Two 
patients refused IT injections. 
 Twelve patients were recruited for IT methylprednisolone 
therapy. All the 12 patients received weekly IT injections 
for three weeks. 
 One month after completion of IT therapy, six of twelve 
patients showed more than 10 dB improvement in the PTA 
test with a median of 19.37 dB (p<0.05). Two patients had 
more than 20 dB hearing improvement. 
 The hearing outcome improved for all the mild, 
moderate and severe-profound hearing loss groups. Mild 
hearing loss group had a 10.9 dB improvement, moderate 
hearing loss improves by 19.07 dB and severe-profound 
improves by 14.69 dB (Figure 1). 
 All the hearing significantly improves after each IT 
injections (p<0.05). The most significant improvement is 
after the third IT therapy (p<0.005) (Table 1).
 We included the hearing thresholds before and after IT 
injections in the four frequencies tested (500, 1000, 2000 
and 4000 Hz). The lowest frequency (500 Hz) had the 
highest gain of 14 dB after IT therapy (p<0.05) followed 
by 4000 Hz at 11.67 dB gained (p<0.05), 2000 Hz at 7.22 
dB (p<0.05) and 1000 Hz at 6.67 dB (p<0.05) (Table 2). 
 In this study, seven out of 12 patients had tinnitus and 
vertigo during the presentation. After IT methylprednisolone 
injections, only one patient suffered continuous tinnitus and 
vertigo while other improves significantly (Figure 2). 
DISCUSSION
There were 32 patients who completed the two weeks 
treatment of systemic corticosteroids therapy. Out of 
these, 18 patients experienced hearing improvement 
of more than 10 dB with two regaining normal hearing 
and 14 patients showed no improvement at all. This was 
comparable with the previous studies done in which 
only 45-75% of patients regained normal hearing after 
SCT (Chandrasekhar 2003; Cinamon et al. 2001; Tucci 
et al. 2002). Those who failed to have any significant 
improvement of more than 10 dB with SCT were 
included in our study and given weekly IT injection of 
methylprednisolone for 3 weeks duration.
 I n  t h e  c u r r e n t  s t u d y,  h i g h e r  d o s a g e  o f 
methylprednisolone (62.5 mg/mL) was selected because 
higher concentration of steroid was proven to be more 
effective as it remained longer in the perilymph (Parnes 
et al. 1999). Ho et al. (2004) later showed that weekly 
intervals of IT corticosteroids for three injections was 
proven to be better compared to the first two injections. In 
TABLE 1. Hearing outcomes after SCT and each IT
Duration Mean of PTA (dB) +/- SD P-value
Post SCT
Post IT procedure week 1
Post IT procedure week 2
Post IT procedure week 3
1 month follow up
56.37 +/- 25.28
55.87 +/- 27.93
50.95 +/-26.98
48.50 +/- 25.86
50.00 +/- 25.66
0.005
0.007
0.005
0.002
0.002
FIGURE 1. Mean PTA average pre and post-therapy according to the level of hearing loss
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2010, Raymundo et al. recruited 14 patients treated with 
three intratympanic methylprednisolone injections after 
failed SCT and showed that ten of 14 (71.4%) patients had 
hearing recovery of more than 20 dB. However, none of 
the mentioned studies used a concentration of more than 
40 mg/mL. The current study is the first report of the use 
of the highest concentration of IT steroid, 62.5 mg/mL, 
with no untoward side effect to the patients after the IT 
procedure. 
 During one month follow up after the completion 
of IT therapy, six of 12 patients showed more than 10 
dB improvement in the PTA with a median of 19.37 dB 
(p<0.05). Four patients had more than 20 dB hearing 
improvement. The improvements in other studies showed 
inconsistent results, with improvements range from 13 
to 75% after IT injections, either as a sole procedure or 
in combination of systemic steroids (Arslan et al. 2011; 
Moon et al. 2011; Spear & Schwartz 2011). This variation 
might be due to the difference in the concentration of 
steroid being used, or other factors such as the duration of 
first treatment and age. In our study, 50% of the patients 
did have improvement after 3 weeks IT procedure using 
high dose of methylprednisolone. This percentage, though 
even is on the higher range, does not prove to be of any 
advantage compared to the lower dosage of steroid done 
in previous studies. In addition, there was no significant 
side effect noted in all of our patients.
 It is well known, factors such as delayed onset of 
treatment and presentation of severe to profound SSNHL, 
are signs of poor prognosis. In the current study, there 
were four patients presented with severe-profound 
sensorineural hearing loss on arrival with the mean PTA 
of 85.00 dB. After completion of the IT therapy, the 
mean PTA improved to 69.7 dB. None of these patients 
later regained normal hearing. However, none of them 
showed deteriorating mean PTA either. In fact, one of the 
patients are able to have improvement from profound to 
severe hearing loss with a PTA average gained of 16.25 
dB. This is also comparable to other studies that showed 
improvement and more importantly the prevention of 
deterioration of hearing loss in severe SSNHL (Battaglia et 
al. 2008; Gundongan et al. 2013; Jong et al. 2010). This 
shows that IT procedure is important not only in gaining 
some recovery but also important in preventing further 
deterioration in severe to profound ISSNHL patients.
 Tinnitus and vertigo are other symptoms associated 
with ISSNHL, which could be a frightening experience 
to the patients. Previous studies have shown that the 
symptom of tinnitus decreased from 70% to 30% after 7 
to 10 days SCT. In IT steroid procedure the improvement is 
much higher, ranging from 75% to 100% (Choi et al. 2013; 
Hyun 2016; Mühlmeier et al. 2016). In the current study, 
in terms of tinnitus, there was a significant improvement 
in 7 out of 8 patients. The same goes with the symptom 
of vertigo, which have a higher range of improvement in 
SSNHL after IT procedure of nearly 100% (Alexander et 
al. 2015; Deenadayal et al. 2016b; She et al. 2009). In our 
study, the vertigo disappears in three out of 4 patients. 
TABLE 2. Hearing Thresholds before and after IT procedure in each frequency
Frequency
(Hz)
Before IT procedure
(Mean PTA, dB) +/- SD
Post procedure
(Mean PTA, dB) +/- SD
PTA differences (dB) 
+/- SD
P-value
(Wilcoxon Test)
500
1000
2000
4000
66.00 +/- 26.20
63.89+/- 27.67
62.22+/- 30.78
60.00+/- 29.63
52.00+/- 21.07
57.22+/- 31.28
55.00+/-29.84
48.33+/- 29.49
14.00+/- 14.65
6.67+/- 15.48
7.22+/- 15.49
11.67+/-14.49
0.05
0.01
0.02
0.03
FIGURE 2. Treatment outcomes in tinnitus and vertigo after IT procedure
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CONCLUSION
The incidence of ISSNHL is rare and in our outpatient 
department accounts for 0.81%. Most of the patients 
presented to the ENT clinic quite early, with a mean of 4.8 
days and all of them received treatment in less than two 
weeks. 
 There were 56.3% of patients with ISSNHL and 
their hearing improves after 2 weeks course of SCT. IT 
methylprednisolone procedure, significantly improves 
the hearing of 50% of the patients who previously not 
responding to SCT. However, these percentages are not 
different from other study that use lower concentration of 
steroid. The higher concentration does not have any short 
or long-term side effect. The procedure is also proven in 
improving the associated symptoms of tinnitus and vertigo. 
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